Overview

First Line Hepato Cellular Carcinoma (HCC)

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Sorafenib